How to Write a Biotech Press Release
How to Write a Biotech Press Release
Quick Answer: A biotech press release is essentially a press release or a public announcement issued by a biotech company about trial results, regulatory filings and approvals, collaborations or funding. These releases must deliver both scientific accuracy and clarity to a lay audience, adhere to stringent editing protocols and be released through trusted channels to the specialist press and the investor media who really care about this sector.
Written by Sarah Whitfield, Senior Biotech PR Strategist. Sarah Whitfield brings 13+ years of experience in biotech press release writing, life sciences media relations, and scientific announcement distribution, working with clinical-stage and publicly traded biotech companies on trial, regulatory, and funding disclosures. This guide is periodically reviewed and revised to ensure alignment with current trends within the biotech industry and media space. Revised: July 2026
One of the most challenging corporate communications documents, in terms of its rigour, is a biotech press release. It should meet the needs of precision by scientists and investors, and it should provide the clarity of journalists. This equilibrium will aid the release to be covered in publications like Fierce Biotech and Yahoo Finance. For a refresher on press release fundamentals before diving into biotech specifics, see our overview on what a press release is and how it works and the broader step-by-step guide to writing a press release.
This guide discusses each component of the biotech press release format, from creating your headline to distribution strategy, as well as provides specific guidelines on how to accurately present clinical data, regulatory language, and investor disclosure. Pairing strong biotech writing with a reliable press release distribution service and solid press release SEO optimization ensures the announcement reaches both journalists and search visibility.
King Newswire distributes biotechnology companies’ announcements to 1000+ verified media outlets with editorial review on every submission.
Biotech PR that leads with a specific clinical or regulatory outcome in the headline is widely recognized among journalists and investors as more likely to earn coverage than releases relying on general statements of progress or development.
Key Points
- The language of a biotech press release needs to be both understandable and accurate. The ratio of these two requirements influences editorial uptake.
- It is essential to ensure that all regulatory language and information about clinical trials are carefully checked in the proofreading stage of the press release in order to prevent any possible problems for the company.
- King Newswire provides news releases to over 1,000 media outlets, including Yahoo Finance, AP News, Nasdaq and MarketWatch. The network reaches both financial media and life sciences publications.
- Press releases released at regulatory dates, trial results or conference dates are far more likely to produce a positive investor and media reaction than a standalone release.
Why Biotech Press Releases Require a Different Approach
Definition: Biotech PR (aka corporate communication) is a formal corporate message designed to inform the media, investors and regulatory stakeholders of a scientifically or commercially important event like a Phase III trial result, an FDA approval, a licensing agreement, etc. This distinguishes it from a general update; see our comparison of a press release versus a media advisory for how the two formats differ.
For most industries, it’s possible to make announcements in a wide and understandable way. Biotechnology cannot. One vague term can confuse investors and be a red flag with respect to regulatory issues. Science journalists will also compare the announcement with primary sources.
A release written only for scientists often overwhelms general readers. Financial journalists and investors also need a clear explanation of the commercial significance.
The structure of your press release should have two levels. You need to start with an informative and goal-oriented headline and first paragraph for reporters and investors. Then provide technically precise body content for scientific readers and regulatory requirements. This layered structure mirrors the standard press release format used across most professional announcements, adapted here for biotech-specific technical depth.
The Biotech Press Release Format That Works
Headline: State the Outcome, Not the Process
The headline of a biotech PR should say what actually happened, not what was investigated. “Company X Reveals 78% Drop in Primary Endpoint in Phase III Study of [Drug Name]” is a good example.
“Company X Reports Progress in Its Ongoing Clinical Studies” isn’t. King Newswire’s editorial team reviews every biotech headline before distribution. The team checks it against the standards used by financial and life sciences editors. For more side-by-side comparisons, browse our collection of press release headline examples that earn coverage.
Opening Paragraph: The Five Ws Plus the Clinical Context
Describe the study, the outcome and the time of the report. Include the location and significance of the data in a clinical or commercial context.
Include one sentence of clinical context (patient size, clinical trial phase, indication being studied). This one paragraph should contain all of the information a financial journalist would brief on an investor-facing summary.
Body Content: Layered Technical Depth
Structure the body in decreasing specificity. The first body paragraph explains the results in plain language. It should also describe what they mean for patients and the company’s pipeline.
The second paragraph provides the data: primary endpoints, p-values, patient numbers, and comparison arms.
The third paragraph explains the regulatory pathway. Include the next submission stage, the responsible agency, and the expected timeline.
This multi-level layout caters to the different segments of the audience; finance reporters could read the introductory section, scientists would refer to the data section, and regulatory analysts would examine the compliance information. Reviewing real examples, such as our curated set of press release examples worth studying, helps illustrate how this layered structure looks once it is written out. Consistent style also matters at the sentence level; our AP style guidelines for press releases cover the grammar and formatting conventions that editors expect.
Quotes: Scientific Authority Plus Commercial Vision
Include two quotes. The first from the Chief Medical Officer or lead investigator focused on clinical significance, patient impact, and scientific rigour.
The second quote should come from the CEO or Chief Business Officer. It should sum up the pipeline impact, business opportunity and strategic importance of the milestone.
All quotes must be from a named individual with a specific title and institutional affiliation as appropriate.
Forward-Looking Statements Disclaimer
Every publicly traded biotechnology company announcement that contains projections, pipeline timelines, or anticipated regulatory outcomes must include a forward-looking statements disclaimer.
This isn’t a fashion statement; it is a legal requirement. King Newswire’s editorial review flags missing disclaimers before distribution. This protects both the company and the announcement’s credibility.
Boilerplate and Media Contact
Conclude with a short company boilerplate on therapeutic focus, pipeline stage and any important partnerships and technologies. Specify a named media contact, rather than a general enquiries address, with a direct email and phone contact.
Life sciences journalists on tight deadlines need immediate access to a person who can answer technical follow-up questions.
Biotech Media Relations: What Specialist Journalists Evaluate
Definition: Biotech media relations is a professional relationship developed and sustained between a biotech company and the journalists, editors and analysts that report on the life sciences sector via regular, precise and prompt communication.
Strong biotech media relations depend on a track record of accurate, well-structured announcements. Life sciences journalists verify primary sources before writing. They compare release claims with published trial data and regulatory filings.
A single inconsistency between a press release and the underlying data damages credibility with specialist media permanently.
King Newswire’s editorial review applies these same verification standards before any biotechnology company announcement reaches distribution, reducing the risk of discrepancies that would otherwise undermine both media coverage and investor confidence. Building this kind of trust starts with choosing the right partner; our guide on choosing the right press release distribution service explains what to evaluate, and working with a full-service press release distribution service like ours keeps that consistency intact across every announcement.
Biotech Press Release Distribution: Timing and Targeting
Definition: Biotech press release distribution is the strategic dissemination of biotechnology announcements across trusted, indexed media channels, synchronising the timing of the dissemination with regulatory calendars, conference agendas and investor relations timelines to maximise the impact of the coverage. For a step-by-step look at the mechanics involved, see our guide on how press release distribution works.
Timing is uniquely critical in biotech. The most effective biotech press release distribution aligns announcements with:
- Conference abstract presentations, where data is first made public
- Regulatory submission confirmations or agency decisions
- Clinical hold lifts or trial resumptions with updated protocols
- Earnings periods, where pipeline progress is material to investor decisions
Investor-focused media coverage tends to be significantly stronger when a biotech firm releases its announcement within 24 hours of a confirmed regulatory or clinical event, since financial journalists and analysts are already watching for the news at that moment.
King Newswire then also pushes biotech news to financial publications, life sciences trade journals and publications that are indexed on Google News. Whether that visibility still translates into ranking benefits is a fair question; our breakdown of whether a press release actually helps SEO looks at what has changed heading into 2026.
Every distribution includes a full post-campaign report listing every publication. Investor relations and communications teams can use it as verified coverage documentation. To budget accordingly, review our breakdown of typical press release distribution costs and our analysis of whether paid press release distribution is worth it. Biotech companies planning multiple announcements across a trial or regulatory timeline can compare press release distribution plans to find the right fit, or work directly with a press release distribution service built for time-sensitive biotech news.
Author Note:
King Newswire distributes biotech press releases and biotechnology company announcements to 1000+ verified media outlets worldwide, including Yahoo Finance, AP News, Nasdaq, and MarketWatch. Editorial review and full post-campaign performance reporting are included on every submission. Ready to put a biotech announcement in front of the right audience? Explore our press release writing and distribution services to get started.
(FAQs)
What is the correct way to present clinical data in a biotech press release?
State the primary endpoint first. Then identify the patient population, trial phase, and statistical significance. Do not lead with secondary endpoints or subgroup analyses, as this can invite regulatory and media scrutiny.
How does King Newswire handle forward-looking statements in biotech announcements?
King Newswire’s editorial review checks every biotechnology company announcement for required disclaimers before distribution, ensuring the release meets the legal disclosure standards of the financial and regulatory outlets in its network.
Should a biotech press release target scientific or financial media?
Both simultaneously. King Newswire reaches life sciences publications and financial outlets through one submission. The network includes Yahoo Finance, Nasdaq and MarketWatch, eliminating the need to run separate campaigns for each audience.
How long should a biotech press release be?
The majority of clinical and regulatory announcements are most effective at between 500 and 650 words. For Phase III readouts, there may be more detail; however, readability is best achieved with clear subheadings.
Can a private biotech company benefit from professional press release distribution?
Yes. Private companies use biotech PR distribution to attract partnership interest, licensing enquiries, and acquisition attention from industry players who monitor sector news through the same financial and trade outlets that King Newswire reaches. Private biotech firms exploring their options can compare press release distribution plans to find a package that matches their announcement volume and budget.
What is the biggest mistake in biotech press release writing?
Burying the primary clinical outcome. The most significant data point, the primary endpoint result, must appear in the headline or the opening sentence. Editors and investors make coverage decisions within seconds based on this single piece of information.
How does biotech media relations benefit from consistent distribution through King Newswire?
Companies that publish consistent, accurate, and well-structured announcements build trust with life sciences journalists over time, which leads to more requests for expert commentary, proactive media coverage, and inclusion in sector round-ups.
When is the best time to distribute a biotech press release for maximum investor visibility?
Tuesday or Wednesday morning, timed to coincide with market open in the primary investor geography. For regulatory decisions, distribute immediately upon a confirmed outcome. Financial markets respond to biotech regulatory news in real time.